We report on a 65-year-old patient with AML refractory to multiple treatment lines, including two allogeneic stem cell transplantations, who received individualized experimental treatment with intravenous GM-CSF and PGE1 and no additional anti-leukaemic therapy. This evidence concerns the gene CSF2 and acute myeloid leukemia.